PPAR gamma-ligands inhibit migration mediated by multiple chemoattractants in vascular smooth muscle cells.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Journal of Cardiovascular Pharmacology

• Publication date

  1999-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1097/00005344-199905000-00018PMID 10226869
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation.

  1998cited by this paper
• Identification of High-Affinity Binding Sites for the Insulin Sensitizer Rosiglitazone (BRL-49653) in Rodent and Human Adipocytes Using a Radioiodinated Ligand for Peroxisomal Proliferator-Activated Receptor γ

  1998cited by this paper
• The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation

  1998cited by this paper
• PPAR-gamma: adipogenic regulator and thiazolidinedione receptor.

  1998cited by this paper
• Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators

  1998cited by this paper
• Adherent neutrophils activate endothelial myosin light chain kinase: role in transendothelial migration.

  1998cited by this paper
• Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators.

  1998cited by this paper
• Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes.

  1998cited by this paper
• Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor gamma.

  1998cited by this paper
• Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in rat aortic smooth muscle cells.

  1998cited by this paper
• Smooth muscle cell migration and proliferation are mediated by distinct phases of activation of the intracellular messenger mitogen-activated protein kinase.

  1998cited by this paper
• Terminal differentiation of human breast cancer through PPAR gamma.

  1998cited by this paper
• Regulation of Cell Motility by Mitogen-activated Protein Kinase

  1997cited by this paper
• Downregulation of cyclin G1 expression by retrovirus-mediated antisense gene transfer inhibits vascular smooth muscle cell proliferation and neointima formation.

  1997cited by this paper
• Thrombin promotes activation of matrix metalloproteinase-2 produced by cultured vascular smooth muscle cells.

  1997cited by this paper
• Perspectives series: cell adhesion in vascular biology. Smooth muscle migration in atherosclerosis and restenosis.

  1997cited by this paper
• Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists

  1997cited by this paper
• Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993.

  1997cited by this paper
• Inhibition of smooth muscle cell migration by the p21 cyclin-dependent kinase inhibitor (Cip1).

  1997cited by this paper
• Fibroblast growth factor receptor signaling activates the human interstitial collagenase promoter via the bipartite Ets-AP1 element.

  1997cited by this paper
• Mitogen-activated protein kinase activation is involved in platelet-derived growth factor-directed migration by vascular smooth muscle cells.

  1997cited by this paper
• Regulated expression of the ets-1 transcription factor in vascular smooth muscle cells in vivo and in vitro.

  1996cited by this paper
• Ligand occupancy of the alpha-V-beta3 integrin is necessary for smooth muscle cells to migrate in response to insulin-like growth factor.

  1996cited by this paper
• Expression of the peroxisome proliferator-activated receptor (PPAR) in the mouse colonic mucosa.

  1996cited by this paper
• Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat.

  1996cited by this paper
• Phosphorylation and activation of smooth muscle myosin light chain kinase by MAP kinase and cyclin-dependent kinase-1.

  1996cited by this paper
• Regulation of PPAR gamma gene expression by nutrition and obesity in rodents.

  1996cited by this paper
• The structure - Activity relationship between peroxisome proliferator-activated receptor γ agonism and the antihyperglycemic activity of thiazolidinediones

  1996cited by this paper
• Multiple growth factors are associated with lesions of atherosclerosis: Specificity or redundancy?

  1996cited by this paper
• Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia.

  1996cited by this paper
• Regulation of vascular smooth muscle cell migration and proliferation in vitro and in injured rat arteries by a synthetic matrix metalloproteinase inhibitor.

  1996cited by this paper
• Phosphorylation-dependent formation of a quaternary complex at the c-fos SRE

  1996cited by this paper
• The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones.

  1996cited by this paper
• ERK phosphorylation potentiates Elk‐1‐mediated ternary complex formation and transactivation.

  1995cited by this paper
• Insulin-like growth factor (IGF)-binding proteins inhibit the smooth muscle cell migration responses to IGF-I and IGF-II.

  1995cited by this paper
• Intracellular signaling pathways required for rat vascular smooth muscle cell migration. Interactions between basic fibroblast growth factor and platelet-derived growth factor.

  1995cited by this paper
• Signalling mechanisms in the regulation of vascular cell migration.

  1995cited by this paper
• Structure and Promoter Characterization of the Human Stromelysin-3 Gene (*)

  1995cited by this paper
• RAR‐specific agonist/antagonists which dissociate transactivation and AP1 transrepression inhibit anchorage‐independent cell proliferation.

  1995cited by this paper
• Thrombin Induces the Activation of Progelatinase A in Vascular Endothelial Cells

  1995cited by this paper
• Calmodulin-dependent autophosphorylation of smooth muscle myosin light chain kinase: intermolecular reaction mechanism via dimerization of the kinase and potentiation of the catalytic activity following activation.

  1995cited by this paper
• 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma.

  1995cited by this paper
• Role of calcium/calmodulin-dependent protein kinase II in the regulation of vascular smooth muscle cell migration.

  1995cited by this paper
• Diabetes and Cardiovascular Disease: The “Common Soil” Hypothesis

  1995cited by this paper
• 15-Deoxy-Δ12,14-Prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ

  1995cited by this paper
• A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation.

  1995cited by this paper
• Insulin-like growth factor-I and platelet-derived growth factor-BB induce directed migration of human arterial smooth muscle cells via signaling pathways that are distinct from those of proliferation.

  1994cited by this paper
• Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone.

  1994cited by this paper
• Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor.

  1994cited by this paper
• A new class of retinoids with selective inhibition of AP-1 inhibits proliferation

  1994cited by this paper
• The mitogen-activated protein kinase signal transduction pathway.

  1993cited by this paper
• Migration of Smooth Muscle and Endothelial Cells: Critical Events in Restenosis

  1992cited by this paper
• Metabolic Effects of New Oral Hypoglycemic Agent CS-045 in NIDDM Subjects

  1992cited by this paper
• Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF

  1991cited by this paper
• Induction of insulin-like growth factor I messenger RNA in rat aorta after balloon denudation.

  1990cited by this paper
• Transcriptional interference between c-Jun and the glucocorticoid receptor: mutual inhibition of DNA binding due to direct protein-protein interaction.

  1990cited by this paper
• Platelet-derived growth factor mRNA detection in human atherosclerotic plaques by in situ hybridization.

  1988cited by this paper
• Attachment of smooth muscle cells to collagen and their migration toward platelet-derived growth factor.

  1981cited by this paper
• The smooth muscle cell in culture.

  1979cited by this paper
• Changes in the tensions of CO2 and O2 in gases injected under the skin and into the abdominal cavity

  1924cited by this paper
• Changes in the tensions of CO(2) and O(2) in gases injected under the skin and into the abdominal cavity.

  year unknowncited by this paper

• Nervonic acid and its sphingolipids: Biological functions and potential food applications

  2023cites this paper
• Pioglitazone inhibits oxidative stress, MMP-mediated inflammation and vascular dysfunction in high glucose-induced human saphenous vein grafts.

  2023cites this paper
• 15-Deoxy-Δ-12,14-prostaglandin J2 effects in vascular smooth muscle cells: Implications in vascular smooth muscle cell proliferation and contractility.

  2021cites this paper
• Peroxisome Proliferator-Activated Receptor γ, but Not α or G-Protein Coupled Estrogen Receptor Drives Functioning of Postnatal Boar Testis—Next Generation Sequencing Analysis

  2021cites this paper
• Stabilizing Peri-Stent Restenosis Using a Novel Therapeutic Carrier

  2019cites this paper
• In vitro mitochondria-mediated anticancer and antiproliferative effects of Annona glabra leaf extract against human leukemia cells.

  2018cites this paper
• Different Effects of Thiazolidinediones on In-Stent Restenosis and Target Lesion Revascularization after PCI: A Meta-Analysis of Randomized Controlled Trials

  2017cites this paper
• Pioglitazone, an anti-diabetic drug requires sustained MAPK activation for its anti-tumor activity in MCF7 breast cancer cells, independent of PPAR-γ pathway

  2016cites this paper
• Peroxisome proliferator-activated receptor γ inhibits pulmonary hypertension targeting store-operated calcium entry

  2015cites this paper
• The Role of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Postangioplasty Restenosis.

  2015cites this paper
• Pioglitazone Suppresses CXCR7 Expression To Inhibit Human Macrophage Chemotaxis through Peroxisome Proliferator-Activated Receptor γ.

  2015cites this paper
• Rac1 modification by an electrophilic 15-deoxy Δ12,14-prostaglandin J2 analog

  2015cites this paper
• Effect of a new PPAR-gamma agonist, lobeglitazone, on neointimal formation after balloon injury in rats and the development of atherosclerosis.

  2015cites this paper
• Cannabinoid Receptor Type 2 (CB2) Dependent and Independent Effects of WIN55,212-2 on Atherosclerosis in Ldlr-null Mice.

  2015cites this paper
• Inhibited proliferation of human umbilical artery smooth muscle cells by xanthinol nicotinate

  2015cites this paper
• Influence of Peroxisome Proliferator-Activated Receptors (PPARs) and Liver X Receptors (LXRs) on Development of Artherosclerosis

  2015cites this paper
• Chronic allograft rejection: A significant hurdle to transplant success

  2014cites this paper
• Ibuprofen inhibits migration and proliferation of human coronary artery smooth muscle cells by inducing a differentiated phenotype: role of peroxisome proliferator‐activated receptor γ

  2014cites this paper
• The ‘collateral benefits‘ of noninsulin therapies for Type 2 diabetes

  2013cites this paper
• Peroxisome proliferator-activated receptor agonists (PPARs): a promising prospect in the treatment of psoriasis and psoriatic arthritis * Os receptores ativados pelo proliferador de peroxissoma (PPAR): uma perspectiva promissora na condução da psoríase e artrite psoriásica

  2013cites this paper
• Peroxisome proliferator-activated receptor agonists (PPARs): a promising prospect in the treatment of psoriasis and psoriatic arthritis

  2013cites this paper
• Peroxisome Proliferator-Activated Receptor γ Agonists Attenuate Hyperglycaemia-Induced Hyaluronan Secretion in Vascular Smooth Muscle Cells by Inhibiting PKCβ2

  2013cites this paper
• Effects of Low Dose Pioglitazone on Restenosis and Coronary Atherosclerosis in Diabetic Patients Undergoing Drug Eluting Stent Implantation

  2013cites this paper
• Effect of cerium oxide nanoparticles to inflammation and oxidative DNA damages in H9c2 cells

  2012cites this paper
• Pigment epithelium-derived factor reduces the PDGF-induced migration and proliferation of human aortic smooth muscle cells through PPARγ activation.

  2012cites this paper
• Metabolic and Additional Vascular Effects of Thiazolidinediones

  2012cites this paper
• The inhibitory effect of dexamethasone on platelet-derived growth factor-induced vascular smooth muscle cell migration through up-regulating PGC-1α expression.

  2011cites this paper
• PPARs and lipid ligands in inflammation and metabolism.

  2011cites this paper
• Is peroxisome proliferator-activated receptor gamma (PPARγ) a therapeutic target for the treatment of pulmonary hypertension?

  2011cites this paper
• Regulator of calcineurin 1 mediates pathological vascular wall remodeling

  2011cites this paper
• Homozygosity for the Ala Allele of the PPARγ2 Pro12Ala Polymorphism Is Associated with Reduced Risk of Coronary Artery Disease

  2011cites this paper
• CD40/CD40L interaction induces E-selectin dependent leukocyte adhesion to human endothelial cells and inhibits endothelial cell migration.

  2011cites this paper
• Chronic CRP-exposure inhibits VEGF-induced endothelial cell migration.

  2010cites this paper
• Coex-Rank: An approach for microarray combined analysis - applications to PPARgamma related datasets

  2010cites this paper
• Smooth muscle cell hypertrophy, proliferation, migration and apoptosis in pulmonary hypertension.

  2010cites this paper
• Rosiglitazone attenuates chronic hypoxia-induced pulmonary hypertension in a mouse model.

  2010cites this paper
• Therapeutic Implications of PPARγ in Cardiovascular Diseases

  2010cites this paper
• Different effects of thiazolidinediones on target vessel revascularization with bare metal stents: a meta-analysis.

  2010cites this paper
• Thiazolidinediones Up-regulate Insulin-like Growth Factor-1 Receptor via a Peroxisome Proliferator-activated Receptor γ-Independent Pathway*

  2010cites this paper
• PPARgamma and the pathobiology of pulmonary arterial hypertension.

  2010cites this paper
• PPARγ as a potential therapeutic target in pulmonary hypertension

  2010cites this paper
• New troglitazone derivatives devoid of PPARγ agonist activity display an increased antiproliferative effect in both hormone-dependent and hormone-independent breast cancer cell lines

  2010cites this paper
• PPARs and the Cardiovascular System

  2009cites this paper
• Peroxisome proliferator-activated receptor gamma and cardiovascular diseases.

  2009cites this paper
• Telmisartan induces proliferation of human endothelial progenitor cells via PPARgamma-dependent PI3K/Akt pathway.

  2009cites this paper
• Impact of telmisartan on coronary stenting in patients with acute myocardial infarction compared with enalapril.

  2009cites this paper
• Comparison of bare metal stent with pioglitazone versus sirolimus-eluting stent for percutaneous coronary intervention in patients with Type 2 diabetes mellitus.

  2009cites this paper
• PGC-1α Is a Key Regulator of Glucose-Induced Proliferation and Migration in Vascular Smooth Muscle Cells

  2009cites this paper
• Antidiabetic Rosiglitazone Reduces Soluble Intercellular Adhesion Molecule-1 Level in Type 2 Diabetic Patients with Coronary Artery Disease

  2008cites this paper
• Thiazolidinediones: Antidiabetic Drugs with Cardiovascular Effects

  2008cites this paper
• Disruption of ERα signalling pathway by PPARγ agonists: evidences of PPARγ-independent events in two hormone-dependent breast cancer cell lines

  2008cites this paper
• Peroxisome Proliferator-Activated Receptor-γ–Mediated Effects in the Vasculature

  2008cites this paper
• ReviewArticle Clinical Use of PPARγ Ligands in Cancer

  2008cites this paper
• Curcumin Modulates SDF-1 / CXCR 4 – Induced Migration of Human Retinal Endothelial Cells ( HRECs )

  2008cites this paper
• Reduced plaque formation induced by rosiglitazone in an STZ-diabetes mouse model of atherosclerosis is associated with downregulation of adhesion molecules.

  2008cites this paper
• Pleiotropic effects of thiazolidinediones

  2008cites this paper
• The effect of pioglitazone on nitric oxide synthase in patients with type 2 diabetes mellitus.

  2008cites this paper
• The Effect of Chlamydia pneumoniae on the Expression of Peroxisome Proliferator-Activated Receptor-γ in Vascular Smooth Muscle Cells

  2008cites this paper
• Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligands: novel pharmacological agents in the treatment of ischemia reperfusion injury.

  2008cites this paper
• Thiazolidinediones-improving endothelial function and potential long-term benefits on cardiovascular disease in subjects with type 2 diabetes.

  2008cites this paper
• Cardiovascular risk and cardiometabolic protection: role of glitazones.

  2008cites this paper
• Fenofibrate and Pioglitazone Do Not Ameliorate the Altered Vascular Reactivity in Aorta of Isoproterenol-treated Rats

  2008cites this paper
• Clinical Use of PPARγ Ligands in Cancer

  2008cites this paper
• Adipocyte Signaling and Lipid Homeostasis: Sequelae of Insulin-Resistant Adipose Tissue Diabetic Cardiomyopathy: The Search for a Unifying Hypothesis Adiposity and Cardiovascular Disorders: Disturbance of the Regulatory System Consisting of Humoral and Neuronal Signals

  2008cites this paper
• Curcumin modulates SDF-1alpha/CXCR4-induced migration of human retinal endothelial cells (HRECs).

  2008cites this paper
• (-)-Epigallocatechin-3-gallate inhibits monocyte chemotactic protein-1 expression in endothelial cells via blocking NF-kappaB signaling.

  2007cites this paper
• (−)-Epigallocatechin-3-gallate inhibits monocyte chemotactic protein-1 expression in endothelial cells via blocking NF-κB signaling

  2007cites this paper
• Overviews of Pathogen Emergence: Which Pathogens Emerge, When and Why?

  2007cites this paper
• Vascular effects of PPARγ activators – From bench to bedside

  2007cites this paper
• PPARs and molecular mechanisms of transrepression.

  2007cites this paper
• PPARs and diabetes-associated atherosclerosis.

  2007cites this paper
• Cardiovascular Disease and Insulin Resistance

  2007cites this paper
• The PROactive trial (PROspective pioglitAzone Clinical Trial In macroVascular Events): what does it mean for primary care physicians?

  2007cites this paper
• Vascular effects of PPARgamma activators - from bench to bedside.

  2007cites this paper
• Rosiglitazone attenuates hypoxia-induced pulmonary arterial remodeling.

  2007cites this paper
• Mechanisms of vascular smooth muscle cell migration.

  2007cites this paper
• Influenza viruses in animal wildlife populations.

  2007cites this paper
• Efficacy and safety of low-dose pioglitazone after primary coronary angioplasty with the use of bare metal stent in patients with acute myocardial infarction and with type 2 diabetes mellitus or impaired glucose tolerance

  2007cites this paper
• A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with type 2 diabetes.

  2006cites this paper
• Obesity, Peroxisome Proliferator-Activated Receptor, and Atherosclerosis in Type 2 Diabetes

  2006cites this paper
• Dual PPAR&agr;/&ggr; Agonist Tesaglitazar Reduces Atherosclerosis in Insulin-Resistant and Hypercholesterolemic ApoE*3Leiden Mice

  2006cites this paper
• Dual PPARalpha/gamma agonist tesaglitazar reduces atherosclerosis in insulin-resistant and hypercholesterolemic ApoE*3Leiden mice.

  2006cites this paper
• Peroxisomal proliferator-activated receptor-gamma agonists induce partial reversion of epithelial-mesenchymal transition in anaplastic thyroid cancer cells.

  2006cites this paper
• Peroxisome Proliferator-Activated Receptor γ Down-Regulates Receptor for Advanced Glycation End Products and Inhibits Smooth Muscle Cell Proliferation in a Diabetic and Nondiabetic Rat Carotid Artery Injury Model

  2006cites this paper
• Peroxisome proliferator-activated receptor gamma agonists: their role as vasoprotective agents in diabetes.

  2006cites this paper
• Chapter 11 Disruption of CREB regulated of gene expression in diabetes

  2006cites this paper
• Thiazolidinediones: antidiabetic drugs with cardiovascular effects.

  2006cites this paper
• Cell cycle and apoptosis genes in atherosclerosis

  2006cites this paper
• The Dual PPARα/γ Agonist Tesaglitazar Reduces Atherosclerosis Development Beyond its Plasma Cholesterol-Lowering Effects in APOE*3Leiden Transgenic Mice

  2006cites this paper
• Vasoreactivity, Inflammation and vascular effects of Thiazolidinediones in Insulin resistance

  2006cites this paper
• PPARγ Gene Transfer Sustains Apoptosis, Inhibits Vascular Smooth Muscle Cell Proliferation, and Reduces Neointima Formation After Balloon Injury in Rats

  2006cites this paper
• Diabetes Mellitus-Associated Atherosclerosis

  2006cites this paper
• Effect of rosiglitazone on plasma adiponectin levels and arterial stiffness in subjects with prediabetes or non-diabetic metabolic syndrome.

  2006cites this paper
• Diabetes mellitus-associated atherosclerosis: mechanisms involved and potential for pharmacological invention.

  2006cites this paper
• Rosiglitazone Attenuates Atherosclerosis in a Model of Insulin Insufficiency Independent of Its Metabolic Effects

  2005cites this paper
• PPARgamma and atherosclerosis.

  2005cites this paper
• Treatment of active psoriatic arthritis with the PPARgamma ligand pioglitazone: an open-label pilot study.

  2005cites this paper
• Insulin alters nuclear factor-lambdaB and peroxisome proliferator-activated receptor-gamma protein expression induced by glycated bovine serum albumin in vascular smooth-muscle cells.

  2005cites this paper
• Impact of thiazolidinedione therapy on atherogenesis

  2005cites this paper
• Extracellular matrix gene expression in the developing mouse aorta

  2005cites this paper